Document is current

Article History

Received: 2 December 2025

Accepted: 19 January 2026

First Online: 26 January 2026

Declarations

:

: The WiZen study was approved by the ethics committee of the TU Dresden (EK95022019) and registered at ClinicalTrials.gov (NCT04334239). Since the analysis relies on pseudonymized, secondary data, individual consent to participate is not required as confirmed by the ethics committee of the TU Dresden (reference number: EK95022019). The study adheres to all relevant ethical standards and guidelines, including the Declaration of Helsinki, the Memorandum on the Assurance of Good Scientific Practice of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), the Memorandum III “Methoden für die Versorgungsforschung” of the Deutsches Netzwerk Versorgungsforschung and the guideline “Good practice secondary data analysis” (GPS) of the German Society for Epidemiology (Deutsche Gesellschaft für Epidemiologie, DGEpi).

: Not applicable.

: OS, CJB and JS work at a university hospital with certified cancer centers, and VB, CB and MR had worked there in the past. In addition, they received funding from the Innovation Committee of the Federal Joint Committee during the conduct of the study. Independently of this study, JS received institutional grants for investigator-initiated research from the GBA, the BMG, BMBF, the EU, the state of Saxony, Novartis, Sanofi, ALK and Pfizer. He also participated in advisory board meetings as a paid consultant for Sanofi, Lilly and ALK. Independently of this study, OS was a paid consultant for Novartis. He is also a member of the certification commission ‘Skin Cancer Centers’ of the German Cancer Society and a member of the expert panel in the project ‘Development of criteria for the evaluation of certificates and quality seals according to § 137a para. 3 sentence 2 no. 7 SGB V’ for the Institute for Quality Assurance and Transparency in Health Care (IQTIG). Independently of this study, CJB received institutional grants for investigator-initiated research from BMS and German Cancer Aid (DKH). She also participated in advisory board meetings as a paid consultant for AstraZeneca, Bayer, BMS, GSK, Merck and MSD. The other authors declare that they have no conflict of interest.